Physician profile
Larry B Dyal
NPI 1871581744
$978.57
in general payments reported to CMS, 2019-2025
23 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.18 · 2020: $30.72 · 2021: $337 · 2022: $238 · 2023: $162 · 2024: $59.61 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $228.18 | 2021-2023 | Krystexxa |
| Bioventus LLC | $104.20 | 2019-2024 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Paragon 28, INC. | $94.21 | 2021 | |
| Paratek Pharmaceuticals, INC. | $63.10 | 2022-2025 | Nuzyra |
| Treace Medical Concepts, INC. | $62.93 | 2022-2025 | |
| Globus Medical, INC. | $48.71 | 2025 | Senza |
| Access Pro Medical, LLC | $44.19 | 2022 | |
| Depuy Synthes Sales INC. | $35.07 | 2021-2025 | Motoband |
| Organogenesis INC. | $34.54 | 2019-2021 | |
| Medtronic, INC. | $31.56 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $28.62 | 2021 | |
| Amgen INC. | $26.60 | 2024 | Krystexxa |
| Nabriva Therapeutics, Plc | $24.49 | 2022 | |
| Triad Life Sciences INC. | $18.56 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $17.44 | 2023 | Exparel, Iovera, Zilretta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $17.29 | 2024 | Qutenza |
| Medtronic Vascular, INC. | $16.24 | 2020 | |
| Boston Scientific Corporation | $15.95 | 2021 | |
| Baudax Bio INC. | $15.59 | 2022 | |
| Acacia Pharma INC | $15.29 | 2021 | |
| Biocomposites INC | $15.11 | 2025 | Stimulan |
| Ibsa Pharma INC. | $13.76 | 2023 | Tirosint, Licart |
| Forte Bio-Pharma LLC | $6.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Dyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.